·	08-01-2005
<sup>6</sup> 7-37-05 MODIFIED Form <b>PTO-1595 RECC</b> (Rev. 10/02)	Q-8 U.S. DEPARTMENT OF COMM U.S. Patent and Trademark
Tathe Director U.S. 60196	103052202
1. Name of conveying party(ies):	Control         Please record the attached original documents or copy thereof.           2. Name and address of receiving party(ies):
Bristol-Myers Squibb Company JUL 2 7 2005	OTSUKA PHARMACEUTICAL CO., LTD. 2-9 Kanda Tsukasa-cho
Additional name(s) of conveying party(ies) and the ched?	I No Chiyoda-ku, Tokyo 101-8535 JAPAN
3. Nature of conveyance:	
Assignment D Merger	
□ Security Agreement □ Change of Name	
□ Other	
Execution Date: June 9, 2005	Additional name(s) & address(es) attached?  Yes  No
4. Application number(s) or patent number(s):	
If this document is being filed together with a new ap	oplication, the execution date of the application is:
A. Patent Application No.(s) 10/968,482	B. Patent No.(s)
Additional num	bers attached?
5. Name and address of party to whom correspondence	
concerning document should be mailed:	
SUGHRUE MION, PLLC	7. Total fee (37 CFR 3.41): \$40.00
WASHINGTON OFFICE	☑ Enclosed.
23373	Authorized to be charged to Deposit Account No. 19-488
CUSTOMER NUMBER	The USPTO is directed and authorized to charge all required
	fees, except for the Issue Fee and the Publication Fee, to Deposition Account No. 19-4880. Please also credit any overpayments to satisfy the set of the s
	Deposit Account.
	8. Deposit Account Number:
	19-4880
	(Attach duplicate copy of this page if paying by deposit account)
9. Statement and signature. 1	NOT USE THIS SPACE
	g information is true and correct and any attached copy is a true copy of
Gordon Kit Reg	
	ding cover sheet, attachments, and documents: 2
	ded with required cover sheet information to:
MAIL STOP ASSIG	NMENT RECORDATION SERVICES
Director of the	U.S. Patent and Trademark Office
A1	P.O. Box 1450
Alex	andria, VA 22313-1450

01 FC:8021

40.00 DP

## ASSIGNMENT

Pursuant to the October 23, 2001 Development and Commercialization Collaboration Agreement for Aripiprazole and/or for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, BRISTOL-MYERS SQUIBB COMPANY (hereinafter referred to as "assignor"), a Delaware corporation having an office at Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, does hereby assign to OTSUKA PHARMACEUTICAL CO., LTD., (hereinafter referred to as "assignee"), having an office at 2-9 Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, 101-8535, JAPAN, the entire right, title and interest in all countries of the world in and to the invention entitled: CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD as described and/or claimed in the application for Letters Patent filed October 19, 2004 in the United States of America and having Application Serial No. 10/968,482. This assignment includes the grant by the assignor to the

assignee of the right to claim priority for the above-described U.S. application under the International Convention for the Protection of Industrial Property and under any other international arrangement to which the United States of America is or hereafter becomes a signatory.

IN WITNESS WHEREOF, assignor has caused this assignment to be executed this day of \_\_\_\_\_, 2005, at Princeton, New Jersey.

BRISTOLAMYERS SOUIBB COMPANY By .

Name: Louis J Title: Vice President and Chief Patent Counsel

STATE OF NEW JERSEY) SS: COUNTY OF MERCER )

There appeared before me the person above-named and acknowledged that he executed the same of his own free will for the purpose set forth, on this  $-\frac{9^{+-}}{2}$  day of  $\frac{1}{2}$ lease . 2005.



Notary Public

PATENT REEL: 016811 FRAME: 0857

**RECORDED: 07/27/2005**